Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix (NACTcervix)
Cancer of Cervix
About this trial
This is an interventional treatment trial for Cancer of Cervix focused on measuring Neoadjuvant chemotherapy, Surgery, Cervix cancer, Concurrent chemoradiation
Eligibility Criteria
Inclusion Criteria: Women with histologically proven invasive squamous cell carcinoma of the uterine cervix, stages IB2-IIB. Age 18-65 years (both inclusive) No evidence of visceral, skeletal or extra-abdominal nodal metastases. No history of prior or present second malignancy Good performance status (Karnofsky performance score > 70 or ECOG PS <2) Normal hematological & biochemical parameters including normal renal function. Presence of associated co-morbid conditions that preclude participation in the study. No prior treatment. Informed consent for participation in the study.
Sites / Locations
- Tata Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
NACT followed by surgery
Concurrent chemoradiotherapy
3 cycles of neoadjuvant chemotherapy (NACT) (Inj.Paclitaxel +Inj.Carboplatin) followed by surgery (radical abdominal hysterectomy Class III , bilateral pelvic lymphadenectomy & lower para aortic lymph node sampling)
Radiation therapy will be administered to whole pelvis followed by intracavitary brachytherapy. Patients will be given chemotherapy (Inj.Cisplatin) concurrently with external beam radiotherapy.